Shares of Viela Bio VIE were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were up 36.17% year over year to ($0.60), which beat the estimate of ($0.70).
Revenue of $9,336,000 declined by 68.88% from the same period last year, which beat the estimate of $5,550,000.
Outlook
Viela Bio hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Technicals
52-week high: $70.66
Company's 52-week low was at $25.02
Price action over last quarter: Up 50.07%
Company Overview
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
